Is Selegiline Hydrochloride Tablets on the market?

Selegiline hydrochloride tablets (Selegiline) is a monoamine oxidase (MAO) inhibitor developed by Zoltan Etchery of HungaryChinoin Pharmaceutical Company. In 1989, selegiline hydrochloride tablets were approved by the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson's disease. Later, in 2006, the FDA also approved a transdermal patch form of the drug. Selegiline hydrochloride tablets are currently on the market in many countries.

Selegiline Hydrochloride Tablets have received FDA approval for specific medical conditions, making it a valuable treatment option for patients with the following indications: Approved as an adjunctive treatment for patients with Parkinson's disease. There is no evidence from controlled studies that selegiline hydrochloride tablets provide any benefit when treated without levodopa. In its transdermal patch formulation, the drug is approved to treat major depressive disorder (MDD) in adults. In addition to FDA-approved indications, selegiline hydrochloride tablets are also used for the following medical diseases, expanding its potential therapeutic applications for the treatment of patients with early-stage Parkinson's disease and attention deficit hyperactivity disorder.

Selegiline Hydrochloride TabletsThe original drug has been launched in China and has entered the scope of Class B medical insurance. The common price per box may be around around RMB 1,000. The price of Selegiline Hydrochloride Tabletsgeneric drugs currently sold overseas is cheaper, and its pharmaceutical ingredients are basically the same as those of the original drug. The price of 5mg*100 tablets per box may be several hundred RMB (the price may fluctuate due to the exchange rate). For more specific prices and drug information, please consult Yaode Medical Consultant.